$ZIOP announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex in combination with the PD-1 inhibitor Libtayo®  for the treatment of recurrent or progressive glioblastoma (rGBM) in adults.

#daytrading #stocks